| abstract |
The present invention relates in particular to the treatment of diseases associated with disorders associated with inflammatory conditions, autoimmune diseases, proliferative diseases, allergies, transplant rejection, disorders involving cartilage turnover, congenital cartilaginous deformities, and / or IL6 or interferon secretion Lt; RTI ID = 0.0 > (I) < / RTI > In particular, the compounds inhibit JAK1, and more particularly JAK1, a member of the tyrosine kinase. The present invention also relates to pharmaceutical compositions comprising said compounds, diseases accompanied by an inflammatory condition by administration of said compounds, autoimmune diseases, proliferative diseases, allergies, transplant rejections, diseases accompanied by disorders of cartilage turnover, congenital cartilage And / or a method for the prevention and / or treatment of diseases associated with excessive secretion of IL6 or interferon. |